<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174278</url>
  </required_header>
  <id_info>
    <org_study_id>96-8123-018</org_study_id>
    <secondary_id>A6281217</secondary_id>
    <nct_id>NCT00174278</nct_id>
  </id_info>
  <brief_title>Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary</brief_title>
  <official_title>Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      To assess the effect of long-term treatment by Genotonorm on linear growth
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1997</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main efficacy variable is the height SDS (SEMPE) before and after treatment.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The standing height of the patients is measured during the inclusion visit and at each follow-up visit.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The height measurements are always performed at the same time of the day by</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>use of a wallmounted device (e.g. Harpenden Stadiometer).</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Each child has to be measured three times, the mean of these measurements is recorded in the Case Report Form as the present height.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The body weight is measured by use of a balance scale.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Puberty stage is assessed (according to Tanner´s cotation) at the same visits as height is measured.</measure>
  </primary_outcome>
  <enrollment>14</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Growth Retardation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All the patients who have benefit during one year of a treatment by Genotonorm during
             the study 94-8123-014

          -  All patients who have stopped during one year will be included if a signed written
             informed consent

        Exclusion Criteria:

          -  Endocrine disease, except well substituted hypothyroidism

          -  Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=96-8123-018&amp;StudyName=Treatment+With+Recombinant+Human+Growth+Hormone+Genotonorm+%28Registered%29+In+Children+With+Short+Stature+Secondary+</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>August 4, 2008</last_update_submitted>
  <last_update_submitted_qc>August 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

